Mab and gefitinib: lebensf effects of drug combinations on tumor growth, HER-2/neu receptor expression and epidermal growth factor and SA HIGEN fraction of hypoxic cells. Clin Cancer Res 2004, 10:2512 2524th WH Ward, PN Cook, AM Slater, DH Davies, GA Holdgate, LR Green. The epidermal growth factor receptor Geldanamycin tyrosine kinase. Study of the reaction mechanism, the research on the structure and the discovery of a potent inhibitor of the base. Biochem Pharmacol. 1994, 48:659 666th TS Wehrman, WJ Raab, Casipit Doyonnas CL R, Pomerantz JH, Blau HM. A system for quantifying dynamic protein interactions defines ar play him in modulating ErbB2 interactions Herceptin. Proc Natl Acad Sci U S A. 2006, 103:19063 19068. Weiner DB, Kokai Y, Wada T, Cohen J, Williams WV, Greene MI.
Association of Tyrosinkinaseaktivit t The oncoprotein Verarbeitungskapazit dd p185neu. Oncogene. 1989, 4:1175 1183rd Winer EP, Cobleigh M, Dickler M, Miller K, L Fehrehbacher, CM Jones, Anderson S, Eberhard D, C. Jones, multicenter phase Agomelatine II study of the efficacy and safety of Tarceva in women with previously treated advanced or metastatic breast cancer. San Antonio Br Can Symp. 2002:445. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, et al. Activity relationships of the synthesis and structure of 6,7-disubstituted nitrile anilinoquinoline third April. Construction of orally active, irreversible inhibitor of the tyrosine kinase receptor t The factor receptor and human epidermal growth factor epidermal growth factor 2 J Med Chem, 2003, 46:49 63rd Wong TW Lee exercise, Yu C, Luo FR, Oppenheimer S, Zhang H, et al.
T Pr clinical antitumor activity T BMS 599626, a pan-HER kinase homodimeric, HER1/HER2 and inhibits signaling heterodimer. Clin Cancer Res 2006, 12:6186 6193rd Page 21 Moasser Oncogene. Author manuscript 6th, April 2011 PMC. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. A unified system for details nger epidermal GW572016 relative to: the relationship between the conformation of the protein, the price and the inhibitory activity of the receptor in tumor cells t of t. Cancer Res 2004, 64:6652 6659th Xie W, Chow LT, Paterson AJ, Chin E, Kudlow JE. Induced expression of ErbB2 oncogene causes hyperplasia epithelium and reversible regulation of expression in the transgenic nozzles TGFalpha M. Oncogene.
1999, 18:3593 3,607th Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, et al. Growth inhibition by immunochemical and functional antique organ different epitopes on the extracellular Ren Ren induced Dom erbB gene product p185 c Int J Cancer doing mediation seconds. 1993, 53:401 408th yakes FM Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin inhibition of phosphatidylinositol-3-kinase and Akt to the impact of collection mediation body p27 for cyclin D1 and antitumor action is required. Cancer Res 2002, 62:4132 4141st Yarden Y. Antique agonists stimulate the K Body through the new kinase oncogene encoded in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci U.S. A. 1990, 87:2569 2573rd Yokoyama H, Ikehara Y, Kodera Y, Ikehara S, Yatabe Y, Y Mochizuki et al. The molecular basis for the sensitivity of t And acquired resistance to gefitinib in HER2 overexpressing gastric cancer cell lines derived from human liv